LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
Podcast: The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Pipeline
Deals
Financings
Articles
Hangzhou Highlightll Pharmaceutical Co. Ltd.
Headquarters:
Hangzhou, China
Website:
http://www.highlightllpharm...
Year Founded:
2017
Status:
Private
BioCentury
|
Dec 21, 2023
Finance
Dec. 20 Quick Takes: CNS and topical TYK2 inhibitor company Sudo raises $116M series B
Plus: Dynamk’s Kranjac launches new equity firm, PureTech reveals newcos and updates from bluebird, Calliditas and Merck
Read More
BioCentury
|
Nov 9, 2023
Deals
China’s strength is innovation on innovation. Western partners are lining up
Deep antibody expertise is a platform for leaps in new assets and technologies as Asia biotechs become increasingly competitive
Read More
BioCentury
|
Mar 23, 2023
Deals
March 23 Quick Takes: Moderna, Generation Bio in non-viral genetic medicines pact
Plus: PureTech sells royalty for Karuna’s schizophrenia asset and updates from Dewpoint, Novo Nordisk, Gilead and more
Read More
BioCentury
|
Jul 3, 2021
Emerging Company Profile
Hangzhou Highlightll: Twice the target, hold the tox
TYK2/JAK1 inhibitor could treat a broad range of autoimmune diseases
Read More
Items per page:
10
1 - 4 of 4